Table 2. Risk of Breast Cancer–Specific Mortality Among Node-Negative Patients, According to the Recurrence Score and Race/Ethnicity.
| Race/ethnicity | No. of patients | No. of deaths from breast cancer | Subdistribution HR (95% CI) | |
|---|---|---|---|---|
| Age-adjusted model | Multivariable modela | |||
| All node-negative patients | ||||
| Non-Hispanic | ||||
| White | 54 945 | 782 | 1 [Reference] | 1 [Reference] |
| Black | 5697 | 126 | 1.82 (1.51-2.20) | 1.66 (1.37-2.02) |
| American Indian/Alaska Native | 295 | 7 | 1.48 (0.62-3.57) | 1.51 (0.63-3.65) |
| Asian/Pacific Islander | 6033 | 50 | 0.73 (0.55-0.97) | 0.67 (0.50-0.90) |
| Hispanic | 6688 | 73 | 1 (0.78-1.27) | 0.94 (0.73-1.19) |
| Patients with recurrence scores of 0-10 | ||||
| Non-Hispanic | ||||
| White | 11 453 | 65 | 1 [Reference] | 1 [Reference] |
| Black | 1192 | 15 | 2.45 (1.39-4.31) | 2.54 (1.44-4.50) |
| American Indian/Alaska Native | 59 | 1 | 4.27 (0.59-30.91) | 5.15 (0.71-37.44) |
| Asian/Pacific Islander | 1318 | 1 | 0.18 (0.02-1.28) | 0.18 (0.02-1.29) |
| Hispanic | 1434 | 8 | 1.42 (0.68-2.96) | 1.15 (0.50-2.67) |
| Patients with recurrence scores of 11-25 | ||||
| Non-Hispanic | ||||
| White | 35 866 | 402 | 1 [Reference] | 1 [Reference] |
| Black | 3498 | 58 | 1.75 (1.33-2.30) | 1.64 (1.23-2.18) |
| American Indian/Alaska Native | 185 | 2 | 1.26 (0.31-5.07) | 1.3 (0.32-5.20) |
| Asian/Pacific Islander | 3830 | 23 | 0.7 (0.46-1.06) | 0.65 (0.42-0.99) |
| Hispanic | 4315 | 31 | 0.84 (0.58-1.21) | 0.81 (0.56-1.17) |
| Patients with recurrence score >25 | ||||
| Non-Hispanic | ||||
| White | 7606 | 315 | 1 [Reference] | 1 [Reference] |
| Black | 1007 | 53 | 1.53 (1.14-2.05) | 1.48 (1.10-1.98) |
| American Indian/Alaska Native | 51 | 2 | 1.09 (0.27-4.38) | 1.11 (0.28-4.49) |
| Asian/Pacific Islander | 885 | 26 | 0.79 (0.53-1.18) | 0.76 (0.51-1.13) |
| Hispanic | 939 | 34 | 1.08 (0.76-1.54) | 1.06 (0.74-1.51) |
Abbreviation: HR, hazard ratio.
a
Multivariable Fine-Gray model with robust SEs adjusted for age, year of diagnosis, tumor size, progesterone receptor status, type of surgery, and administration of radiotherapy and chemotherapy.